This article has been updated with additional information about the availability of an FDA-approved companion diagnostic for Zykadia. Roche announced FDA approved its Ventana ALK (D5F3) test on June 1.
NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved an expanded indication for Novartis' Zykadia (ceritinib), making it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.